Loading
Life sciences · Phase 1/2 Trial
ClinicalTrials.gov · September 25, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 1/2 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07670312). This is a study registration, not published results. Lead sponsor: XYone Therapeutics, Inc. Recruitment status: RECRUITING. Phase: PHASE1, PHASE2. Study type: INTERVENTIONAL. Enrollment: 190 participants (ESTIMATED). Conditions: MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, GEJ Adenocarcinoma, Colorectal Cancer, Pancreatic Adenocarcinoma, Gastric Cancer. Interventions: BIOLOGICAL: XYA02. Primary outcome measures: Frequency of Treatment Emergent Adverse Events of XYA02 , From enrollment for a minimum of 16 weeks; Duration of Treatment Emergent Adverse Events of XYA02 , From enrollment for a minimum of 16 weeks; Severity of Treatment Emergent Adverse Events of XYA02 , From enrollment for a minimum of 16 weeks; Determine the Maximum Tolerated Dose (MTD) of XYA02 , From enrollment to a minimum of 16 weeks per participant. Brief summary: This study will evaluate the safety, tolerability, and efficacy of XYA02 in participants with advanced solid tumors.